论文部分内容阅读
目的:探讨自主研发产物--斑蝥素酸镁对人喉癌上皮细胞的增殖抑制活性是否好于临床抗癌药物斑蝥酸钠。方法:采用磺酰罗丹明染色法(SRB法)、细胞集落形成实验分别考察斑蝥素酸镁和斑蝥酸钠对人喉癌上皮细胞Hep-2的影响。结果:与斑蝥酸钠相比,斑蝥素酸镁作用喉癌Hep-2细胞的效果更加显著。其IC50仅为2.19μmol·L-1,远低于斑蝥酸钠的IC50(15.75μmol·L-1)。细胞集落形成实验显示,与斑蝥酸钠相比,斑蝥素酸镁明显阻止细胞集落的形成,最低有效浓度为1.75μmol·L-1,远低于斑蝥酸钠的最低有效浓度(3.50μmol·L-1)。结论:与斑蝥酸钠相比,斑蝥素酸镁对喉癌Hep-2细胞具有更加显著的抑制效果,可进行更加深入的研究。
OBJECTIVE: To investigate whether the inhibitory activity of cantharidin magnesium on the proliferation of human laryngeal epithelial cells is better than that of the clinical anti-cancer drug cantharidin. Methods: The effects of sodium cantharidate and sodium cantharidate on human laryngeal epithelial cells Hep-2 were examined by SRB method and colony formation assay. RESULTS: Compared with sodium cantharidate, magnesium cantharidate was more effective on laryngeal carcinoma Hep-2 cells. The IC50 was only 2.19μmol·L-1, much lower than the IC50 of sodium cantharidate (15.75μmol·L-1). Cell colony formation assay showed that compared with sodium cantharidate, magnesium cantharidin significantly prevented the formation of cell colonies with the lowest effective concentration of 1.75 μmol·L-1, much lower than the lowest effective concentration of sodium cantharidate (3.50 μmol·L -1). CONCLUSION: Compared with sodium cantharidate, magnesium cantharidin has more significant inhibitory effect on laryngeal carcinoma Hep-2 cells, which can be further studied.